NCT06141655

HD vs SD Quadrivalent Influenza Vaccine in Adults Aged 65 to 79 Years in Galicia

Name: Clinical Trial NCT06141655
Creator: Federico Martinón Torres
Keywords: Influenza, Influenza vaccine, Phase 4, drug, clinical trial, Spain

Pragmatic Randomized Trial to Evaluate the Effectiveness of High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in Adults Aged 65 to 79 Years in Galicia, Spain

Federico Martinón Torres·Phase 4·ClinicalTrials.gov·drugRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Influenza
Drug/Device/Intervention: Influenza vaccine
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Federico Martinón Torres
Funder: Hospital Clinico Universitario de Santiago
Location: Santiago de Compostela, Spain

Timeline & enrollment

Phase: Phase 4
Start date: Oct 26, 2023
End date: Aug 01, 2025
Enrollment: 114011 participants

Primary outcome

Occurrence of a hospitalization due to influenza or pneumonia

Summary

This pragmatic randomized trial is designed to evaluate the relative vaccine effectiveness of QIV-HD vs. QIV-SD in reducing the risk of hospitalization for influenza or pneumonia in adults 65-79 years of age in Galicia during 2023/2024 and 2024/2025 seasons.

ICD-10 classifications

Influenza and pneumoniaInfluenza due to identified seasonal influenza virusInfluenza with other manifestations, seasonal influenza virus identifiedInfluenza with pneumonia, seasonal influenza virus identifiedInfluenza due to identified zoonotic or pandemic influenza virus

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06141655
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06141655 through Pure Global AI's free database. This Phase 4 trial is sponsored by Federico Martinón Torres and is currently Recruiting. The study focuses on Influenza. Target enrollment is 114011 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.